Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBNX Beta Bionics	$16.40 -2.3%	$15.71	$8.89 ▼ $24.50	$729.86M	N/A	527,705 shs	514,719 shs
EMBC Embecta	$9.96 -2.0%	$10.27	$9.20 ▼ $21.48	$593.78M	1.08	522,700 shs	673,486 shs
IRMD iRadimed	$66.17 +13.4%	$58.63	$42.34 ▼ $66.50	$741.80M	0.94	40,089 shs	108,444 shs
SGHT Sight Sciences	$3.27 -1.8%	$3.83	$2.03 ▼ $7.12	$172.15M	2.45	112,255 shs	229,807 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBNX Beta Bionics	-2.32%	+10.51%	+15.98%	+38.63%	+1,639,999,900.00%
EMBC Embecta	-1.97%	-15.09%	-2.83%	-21.76%	-36.44%
IRMD iRadimed	+13.42%	+17.49%	+7.52%	+23.75%	+41.66%
SGHT Sight Sciences	-1.80%	-6.30%	-21.39%	+7.21%	-57.97%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BBNX Beta Bionics	2.3503 of 5 stars	4.4	0.0	0.0	0.0	1.9	0.8	0.0
EMBC Embecta	4.6458 of 5 stars	3.2	3.0	3.3	0.0	2.7	3.3	3.8
IRMD iRadimed	4.1955 of 5 stars	1.5	3.0	2.5	4.4	2.0	3.3	1.9
SGHT Sight Sciences	2.092 of 5 stars	2.1	4.0	0.0	0.0	1.8	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BBNX Beta Bionics	2.75	Moderate Buy	$22.56	37.53% Upside
EMBC Embecta	2.33	Hold	$19.00	90.76% Upside
IRMD iRadimed	3.00	Buy	$72.00	8.81% Upside
SGHT Sight Sciences	2.29	Hold	$3.93	20.29% Upside

Current Analyst Ratings Breakdown

Latest SGHT, IRMD, EMBC, and BBNX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/30/2025	BBNX Beta Bionics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$18.00 ➝ $21.00
7/30/2025	BBNX Beta Bionics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Neutral ➝ Neutral	$15.00 ➝ $17.00
7/16/2025	EMBC Embecta	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$13.00 ➝ $12.00
7/15/2025	SGHT Sight Sciences	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$3.00 ➝ $4.00
6/18/2025	SGHT Sight Sciences	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$3.50 ➝ $4.00
6/16/2025	BBNX Beta Bionics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$26.00
6/12/2025	BBNX Beta Bionics	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$30.00
5/30/2025	BBNX Beta Bionics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$16.00
5/30/2025	BBNX Beta Bionics	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$20.00
5/23/2025	EMBC Embecta	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$25.00
5/23/2025	EMBC Embecta	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$15.00 ➝ $13.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BBNX Beta Bionics	$65.12M	10.95	N/A	N/A	$6.94 per share	2.36
EMBC Embecta	$1.08B	0.54	$3.27 per share	3.05	($12.80) per share	-0.78
IRMD iRadimed	$73.24M	11.49	$1.79 per share	36.87	$6.85 per share	9.66
SGHT Sight Sciences	$79.87M	2.12	N/A	N/A	$1.72 per share	1.90

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BBNX Beta Bionics	-$54.76M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
EMBC Embecta	$78.30M	$0.90	11.07	3.24	0.65	4.89%	-19.67%	12.27%	8/8/2025 (Estimated)
IRMD iRadimed	$19.23M	$1.55	42.69	33.09	N/A	26.33%	23.28%	20.59%	N/A
SGHT Sight Sciences	-$51.51M	-$0.98	N/A	N/A	N/A	-63.24%	-54.62%	-34.92%	8/7/2025 (Estimated)

Latest SGHT, IRMD, EMBC, and BBNX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/8/2025	Q3 2025	EMBC Embecta	$0.7720	N/A	N/A	N/A	$278.15 million	N/A
8/7/2025	Q2 2025	SGHT Sight Sciences	-$0.25	N/A	N/A	N/A	$18.18 million	N/A
8/1/2025	Q2 2025	IRMD iRadimed	$0.45	$0.45	N/A	$0.45	$20.01 million	$20.41 million
7/29/2025	Q2 2025	BBNX Beta Bionics	-$0.51	-$0.39	+$0.12	-$0.39	$19.73 million	$23.24 million
5/9/2025	Q2 2025	EMBC Embecta	$0.66	$0.70	+$0.04	$0.40	$261.77 million	$259.00 million
5/8/2025	Q1 2025	SGHT Sight Sciences	-$0.29	-$0.28	+$0.01	-$0.28	$16.51 million	$17.51 million
5/6/2025	Q1 2025	BBNX Beta Bionics	-$0.51	-$0.52	-$0.01	-$0.93	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BBNX Beta Bionics	N/A	N/A	N/A	N/A	N/A
EMBC Embecta	$0.60	6.02%	N/A	66.67%	N/A
IRMD iRadimed	$0.68	1.03%	N/A	43.87%	1 Years
SGHT Sight Sciences	N/A	N/A	N/A	N/A	N/A

Latest SGHT, IRMD, EMBC, and BBNX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
8/1/2025	IRMD iRadimed	quarterly	$0.17	1.13%		8/18/2025	8/28/2025
5/5/2025	EMBC Embecta	quarterly	$0.15	4.51%	5/28/2025	5/28/2025	6/13/2025
5/5/2025	IRMD iRadimed	quarterly	$0.17	1.3%	5/20/2025	5/20/2025	5/30/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BBNX Beta Bionics	N/A	14.68	14.93
EMBC Embecta	N/A	2.48	1.83
IRMD iRadimed	N/A	8.87	7.62
SGHT Sight Sciences	0.51	10.47	9.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BBNX Beta Bionics	N/A
EMBC Embecta	93.83%
IRMD iRadimed	92.34%
SGHT Sight Sciences	55.51%

Insider Ownership

Company	Insider Ownership
BBNX Beta Bionics	N/A
EMBC Embecta	0.42%
IRMD iRadimed	36.80%
SGHT Sight Sciences	30.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BBNX Beta Bionics	294	43.47 million	N/A	N/A
EMBC Embecta	2,100	58.44 million	58.20 million	Optionable
IRMD iRadimed	110	12.72 million	8.04 million	Optionable
SGHT Sight Sciences	210	51.70 million	35.72 million	Optionable

SGHT, IRMD, EMBC, and BBNX Headlines

Recent News About These Companies

Sight Sciences (SGHT) Projected to Post Earnings on Thursday

July 31 at 3:38 AM | marketbeat.com

Sight Sciences Announces the Results of a Cost-Utility Analysis Demonstrating Cost Savings and Greater Health Utility with the TearCare® System Compared to Cyclosporine 0.05% ...

July 30 at 12:00 PM | manilatimes.netM

Sight Sciences Announces the Results of a Cost-Utility Analysis Demonstrating Cost Savings and Greater Health Utility with the TearCare® System Compared to Cyclosporine 0.05% for Treating Meibomian Gland Disease-Associated Dry Eye Disease

July 30 at 7:00 AM | globenewswire.com

Sight Sciences Announces the Publication of the 24-Month Results of the SAHARA RCT Demonstrating the Durability of the TearCare® Procedure for the Treatment of Dry Eye Disease

July 29, 2025 | globenewswire.com

Sight Sciences to Report Second Quarter 2025 Financial Results on August 7, 2025

July 24, 2025 | globenewswire.com

Sight Sciences, Inc. (NASDAQ:SGHT) Given Consensus Rating of "Hold" by Brokerages

July 19, 2025 | marketbeat.com

Wall Street Zen Downgrades Sight Sciences (NASDAQ:SGHT) to Sell

July 19, 2025 | marketbeat.com

7SGHT : The Analyst Verdict: Sight Sciences In The Eyes Of 4...

July 15, 2025 | benzinga.com

Sight Sciences (NASDAQ:SGHT) Given New $4.00 Price Target at Morgan Stanley

July 15, 2025 | marketbeat.com

Sight Sciences, Inc. (NASDAQ:SGHT) Insider Matthew Link Sells 4,889 Shares

July 8, 2025 | insidertrades.com

Insider Selling: Sight Sciences, Inc. (NASDAQ:SGHT) Insider Sells 4,889 Shares of Stock

July 7, 2025 | marketbeat.com

Sight Sciences, Inc. (NASDAQ:SGHT) CTO Sells $23,681.43 in Stock

July 7, 2025 | marketbeat.com

Sight Sciences, Inc. (NASDAQ:SGHT) Insider Sells $38,197.20 in Stock

July 7, 2025 | marketbeat.com

Insider Selling: Sight Sciences, Inc. (NASDAQ:SGHT) CEO Sells 23,637 Shares of Stock

July 7, 2025 | marketbeat.com

SGHT - Sight Sciences Inc Chart - Morningstar

July 5, 2025 | morningstar.comM

Sight Sciences Leads The Pack Of 3 Promising Penny Stocks

June 24, 2025 | uk.finance.yahoo.com

sight sciences appoints new board member and holds annual meeting

June 7, 2025 | uk.investing.com

Sight Sciences to Present at the Stifel 2025 Virtual Ophthalmology Forum on May 27th

May 14, 2025 | globenewswire.com

Sight Sciences stock holds as Needham reiterates rating

May 11, 2025 | uk.investing.com

Sight Sciences, Inc. (SGHT) Q1 2025 Earnings Call Transcript

May 11, 2025 | seekingalpha.com

Sight Sciences, Inc. (NASDAQ:SGHT) Q1 2025 Earnings Call Transcript

May 10, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGHT, IRMD, EMBC, and BBNX Company Descriptions

Beta Bionics NASDAQ:BBNX

$16.40 -0.39 (-2.32%)

As of 08/1/2025 04:00 PM Eastern

Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.

Embecta NASDAQ:EMBC

$9.96 -0.20 (-1.97%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$10.06 +0.10 (+1.00%)

As of 08/1/2025 05:09 PM Eastern

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.

iRadimed NASDAQ:IRMD

$66.17 +7.83 (+13.42%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$66.05 -0.12 (-0.18%)

As of 08/1/2025 07:41 PM Eastern

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.

Sight Sciences NASDAQ:SGHT

$3.27 -0.06 (-1.80%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$3.28 +0.00 (+0.15%)

As of 08/1/2025 04:10 PM Eastern

Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time